Drug‐Drug, Drug—Dietary Supplement, and Drug—Citrus Fruit and Other Food Interactions: What Have We Learned?
- 1 June 2004
- journal article
- review article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 44 (6), 559-569
- https://doi.org/10.1177/0091270004265367
Abstract
Serious drug-drug interactions have contributed to recent U.S. market withdrawals and also recent nonapprovals of a few new molecular entities. Many of these interactions involved the inhibition or induction of metabolizing enzymes and efflux transporters, resulting in altered systemic exposure and adverse drug reactions or loss of efficacy. In addition to drug-drug interactions, drug-dietary supplement and drug-citrus fruit interactions, among others, could also cause adverse drug reactions or loss of efficacy and are important issues to consider in the evaluation of new drug candidates. This commentary reviews (1). the current understanding of the mechanistic basis of these interactions, (2). issues to consider in the interpretation of study results, and (3). recent labeling examples to illustrate the translation of study results to information useful for patients and health care providers.Keywords
This publication has 54 references indexed in Scilit:
- The interaction between St John's wort and an oral contraceptiveClinical Pharmacology & Therapeutics, 2003
- THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVEDrug Metabolism and Disposition, 2003
- Drug–drug interaction mediated by inhibition and induction of P-glycoproteinAdvanced Drug Delivery Reviews, 2003
- Role of P-Glycoprotein in PharmacokineticsClinical Pharmacokinetics, 2003
- Lack of Bioequivalence of Ciprofloxacin When Administered with Calcium‐Fortified Orange Juice: A New Twist on an Old InteractionThe Journal of Clinical Pharmacology, 2002
- Use of Complementary Medicine by Adult Patients Participating in HIV/AIDS Clinical TrialsThe Journal of Alternative and Complementary Medicine, 2000
- Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activityPublished by Wiley ,1999
- Assessment of the Quality and Quantity of Drug‐Drug Interaction Studies in Recent NDA Submissions: Study Design and Data Analysis IssuesThe Journal of Clinical Pharmacology, 1999
- FDA Evaluations Using In Vitro Metabolism to Predict and Interpret In Vivo Metabolic Drug‐Drug Interactions: Impact on LabelingThe Journal of Clinical Pharmacology, 1999
- Effect of grapefruit juice on blood cyclosporin concentrationThe Lancet, 1995